oral semaglutide in obesity
In the UK, semaglutide tablets are now licensed for use in adults with a BMI of 30 or above, or who are overweight (BMI 27-30) with at least one weight-related comorbidity (1).
The starting dose is 1.5mg daily, increasing to 4mg, 9mg and 25mg with a minimum duration of one month at each dose level.
“..Patients currently treated privately with a 2.4 mg semaglutide injection once weekly can be transitioned straight to semaglutide 25 mg tablets once daily..” (1).
Reference:
- MHRA (June 11th 2026). First GLP-1 tablet for weight loss approved in the UK.
Related pages
Create an account to add page annotations
Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page